Everett E. Vokes, MD | Authors

Treatment of Advanced Head and Neck Cancer: Past, Present, and Future

September 01, 2008

Bruce Culliney and colleagues have provided a thorough and well written summary of the literature regarding multimodality treatment of patients with locoregionally advanced or unresectable head and neck malignancies. In particular, they offer a detailed outline of recent insights into radiation dosing and fractionation and their optimal use in the combined-modality setting.

Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, and Head and Neck Cancers

April 29, 2006

Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types. While both inhibit the EGFR pathway, they act via different mechanisms.

Commentary (Brockstein/Vokes): Revisiting Induction Chemotherapy for Head and Neck Cancer

June 01, 2005

Argiris et al present a comprehensivereview of inductionchemotherapy for head andneck cancer, and should be lauded fortheir meticulous work. This papercarefully delineates and categorizesmost of the relevant induction chemotherapystudies in head and neckcancer performed over the past 3 decades.The authors have sought to answerquestions regarding the optimalnumber of chemotherapy cycles (acritical factor when one uses responseto induction chemotherapy to determineeligibility for organ preservationor in an attempt to enhance curerates), the optimal chemotherapyregimen, and the possibility of a sitespecificbenefit to induction chemotherapy.The paper assesses benefitbased on treatment intent-that is, organpreservation vs survival benefit.Importantly, by excavating the layersof the past, the authors provide aframework with which to construct anew paradigm of treatment for headand neck cancer that may again incorporateinduction chemotherapy.

Commentary (Cohen/Vokes): Gene Therapy for Head and Neck Cancers

March 01, 2001

This issue of Oncology features an excellent review of gene therapy for head and neck cancers. Lamont and colleagues have highlighted the principles of genetic intervention, the current state of available therapies, and the results of human trials in an organized and coherent manner.

Chemoradiation for Locally Advanced, Unresectable NSCLC

August 01, 1999

The optimal therapy for locally advanced, unresectable, stage III non–small-cell lung cancer (NSCLC) continues to evolve. The critical determinants of overall survival include local tumor control and the

Oral 5-FU Alternatives for the Treatment of Head and Neck Cancer

October 01, 1998

The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients).

Doublets and Triplets: New Drug Combinations in the Palliative Care of NSCLC

October 02, 1997

Chemotherapy has been shown to prolong survival in patients with stage IV non-small-cell lung cancer (NSCLC). However, traditional cisplatin (Platinol)-containing regimens are associated with significant toxicity.

Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies

October 02, 1997

Newer chemotherapy drugs have shown encouraging activity in advanced non-small-cell lung cancer. Based on these improved outcomes, as well as the high rate of distant relapse in patients with locally advanced disease, several recent studies have evaluated the use of systemic therapy in patients with earlier-stage disease.

Combined-Modality Therapy of Head and Neck Cancer

September 01, 1997

The treatment of head and neck cancer has traditionally consisted of surgery with postoperative radiation therapy. Chemotherapy has been reserved for palliation.

Phase I Study of Docetaxel and Concomitant Chest Radiation

July 01, 1997

Data from the Radiation Therapy Oncology Groupand Eastern Cooperative Oncology Group indicate that increased survival